EUVIMEDEUVIMED entdecken
Crossref

Dysregulated Expression of Tim-3 and NKp30 Receptors on NK Cells of Patients with Chronic Lymphocytic Leukemia

Leila Hadadi, Morteza Hafezi, Ali Akbar Amirzargar, Ramazan Ali Sharifian, Saeid Abediankenari, Hossein Asgarian-Omran

Oncology Research and Treatment · 2019 · 42 (4) · 197-203

DOI: 10.1159/000497208 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology Research and Treatment, online erschienen am 14.03.2019. Verfasst von Leila Hadadi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 44 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In this study, the expression pattern of NKp30 and T cell immunoglobulin and mucin domain-containing molecule-3 (Tim-3), as candidates for activating and inhibitory receptors of NK cells, were evaluated in patients with chronic lymphocytic leukemia (CLL). Patients and Methods: 24 CLL patients and 19 healthy controls were enrolled. Fresh peripheral blood was collected from all subjects and stained with fluorochrome-conjugated antibodies. The frequency of CD56+/CD3–/NKp30+ and CD56+/CD3–/Tim-3+ cells was determined by multicolor flow cytometry.

Results

Our results revealed that Tim-3 is significantly upregulated on natural killer (NK) cells of CLL patients in comparison to healthy controls. NK cells of CLL patients showed lower expression of NKp30-activating receptor compared to controls. Tim-3 expression pattern on NK cells of CLL patients was correlated with poor prognostic factors including low hemoglobin level, high absolute lymphocyte count, and high serum C-reactive protein level.

Conclusion

Dysregulated expression of Tim-3 and NKp30 receptors confirms the exhaustion state of NK cells in CLL. Our data introduce Tim-3 as a promising biomarker and potential target for immunotherapy of CLL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AgedAged, 80 and overCase-Control StudiesFemaleGene Expression RegulationHepatitis A Virus Cellular Receptor 2HumansKiller Cells, NaturalLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedNatural Cytotoxicity Triggering Receptor 3

Stichwörter der Autor:innen

Chronic lymphocytic leukemiaNK cellsNKp30Tim-3

Substanzen

Hepatitis A Virus Cellular Receptor 2Natural Cytotoxicity Triggering Receptor 3

Autor:innen und Institutionen

  • Department of Immunology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
  • Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Immunology, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Clinic of Hematology and Oncology, Vali-Asr Hospital, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Immunogenetics Research Center, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
  • Department of Immunology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran, asgarianhossein@yahoo.com.

Zitieren

APA

Hadadi, L., Hafezi, M., Amirzargar, A. A., Sharifian, R. A., Abediankenari, S., & Asgarian-Omran, H. (2019). Dysregulated Expression of Tim-3 and NKp30 Receptors on NK Cells of Patients with Chronic Lymphocytic Leukemia. Oncology Research and Treatment, 42(4), 197-203. https://doi.org/10.1159/000497208

Vancouver

Hadadi L, Hafezi M, Amirzargar AA, Sharifian RA, Abediankenari S, Asgarian-Omran H. Dysregulated Expression of Tim-3 and NKp30 Receptors on NK Cells of Patients with Chronic Lymphocytic Leukemia. Oncology Research and Treatment. 2019;42(4):197-203. doi:10.1159/000497208

BibTeX
@article{Hadadi2019,
  author = {Hadadi, Leila and Hafezi, Morteza and Amirzargar, Ali Akbar and Sharifian, Ramazan Ali and Abediankenari, Saeid and Asgarian-Omran, Hossein},
  title = {Dysregulated Expression of Tim-3 and NKp30 Receptors on NK Cells of Patients with Chronic Lymphocytic Leukemia},
  journal = {Oncology Research and Treatment},
  year = {2019},
  volume = {42},
  number = {4},
  pages = {197--203},
  doi = {10.1159/000497208}
}
Kostenlos starten →